{
  "source": "PA-Notification-Ninlaro.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1173-12\nProgram Prior Authorization/Notification\nMedication Ninlaro® (ixazomib)\nP&T Approval Date 1/2016, 4/2016, 3/2017, 3/2018, 3/2019, 3/2020, 3/2021, 3/2022,\n3/2023, 3/2024, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nNinlaro (ixazomib) is a proteasome inhibitor indicated in combination with lenalidomide and\ndexamethasone for the treatment of patients with multiple myeloma who have received at least\none prior therapy.\nLimitations of Use:\nNinlaro is not recommended for use in the maintenance setting or in newly diagnosed multiple\nmyeloma in combination with lenalidomide and dexamethasone outside of controlled clinical\ntrials.\nThe National Comprehensive Cancer Network (NCCN) also recommends use of Ninlaro as\nprimary or maintenance therapy for multiple myeloma, for treatment of relapsed or refractory\nsystemic light chain amyloidosis, and for treatment of Waldenström\nmacroglobulinemia/lymphoplasmacytic lymphoma in combination with rituximab and\ndexamethasone.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Ninlaro will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Multiple Myeloma\n1. Initial Authorization\n© 2025 UnitedHealthcare Services, Inc.\n1\na. Ninlaro will be approved based on the following criterion:\n(1) Diagnosis of multiple myeloma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na.",
    "2025 UnitedHealthcare Services, Inc.\n1\na. Ninlaro will be approved based on the following criterion:\n(1) Diagnosis of multiple myeloma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ninlaro will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Ninlaro therapy\nAuthorization will be issued for 12 months.\nC. Systemic Light Chain Amyloidosis\n1. Initial authorization\na. Ninlaro will be approved based on the following criterion:\n(1) Diagnosis of relapsed or refractory systemic light chain amyloidosis\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ninlaro will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Ninlaro therapy\nAuthorization will be issued for 12 months.\nD. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma\n1. Initial authorization\na. Ninlaro will be approved based on both of the following criteria:\n(1) Diagnosis of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma\n-AND-\n(2) Used in combination with Rituxan (rituximab) and dexamethasone\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ninlaro will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services, Inc.\n2\n(1) Patient does not show evidence of progressive disease while on Ninlaro therapy\nAuthorization will be issued for 12 months.\nE. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcar",
    "enefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Ninlaro [package insert]. Cambridge, MA: Takeda Pharmaceutical Company Ltd.; July 2024\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org. Accessed May 2, 2025.\nProgram Prior Authorization/Notification – Ninlaro (ixazomib)\nChange Control\n1/2016 New program.\n4/2016 Removed Revlimid & dexamethasone requirement from coverage criteria\nper NCCN. Updated background and references.\n3/2017 Annual Review. Updated background information and criteria to include\nNCCN recommendation for primary use in combination with Revlimid\nand dexamethasone.\n3/2018 Annual review with no changes to coverage criteria. Updated reference.\n3/2019 Annual review. Updated background information and criteria to include\nNCCN recommendation for relapsed/refractory systemic light chain\namyloidosis. Updated criteria for multiple myeloma as Ninlaro is no\nlonger recommended alone for relapsed or progressive disease. Updated\nreference.\n3/2020 Annual review. Updated background information and criteria to include\nNCCN recommendation for transplant candidates, and Waldenström\n© 2025 UnitedHealthcare Services, Inc.\n3\nMacroglobulinemia/Lymphoplasmacytic Lymphoma. Added standard\nlanguage for NCCN recommended regimens. Updated reference.\n3/2021 Annual review. Updated references.\n3/2022 Annual review. Updated references.\n3/2023 Annual review with no change to coverage criteria. Updated background\nand references. Added state mandate footnote.\n3/2024 Annual review. Updated background and coverage",
    "ew. Updated references.\n3/2023 Annual review with no change to coverage criteria. Updated background\nand references. Added state mandate footnote.\n3/2024 Annual review. Updated background and coverage criteria per NCCN\nguidelines. Updated references.\n6/2024 Updated Multiple Myeloma criteria to only diagnosis.\n6/2025 Annual review with no change to coverage criteria. Updated background\nand reference.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}